-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $200

Benzinga·01/21/2026 14:25:47
Listen to the news
RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $197 to $200.